First Trust Advisors LP Sells 11,601 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

First Trust Advisors LP lowered its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 8.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 129,691 shares of the specialty pharmaceutical company's stock after selling 11,601 shares during the quarter. First Trust Advisors LP owned about 0.40% of Collegium Pharmaceutical worth $3,716,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. JPMorgan Chase & Co. grew its holdings in Collegium Pharmaceutical by 173.6% in the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company's stock worth $10,711,000 after purchasing an additional 175,892 shares during the period. Barclays PLC grew its stake in shares of Collegium Pharmaceutical by 152.2% in the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company's stock valued at $2,899,000 after buying an additional 45,291 shares during the period. Principal Financial Group Inc. increased its position in Collegium Pharmaceutical by 3.9% in the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company's stock valued at $67,459,000 after buying an additional 64,958 shares in the last quarter. Sanctuary Advisors LLC raised its stake in Collegium Pharmaceutical by 5.3% during the 4th quarter. Sanctuary Advisors LLC now owns 18,928 shares of the specialty pharmaceutical company's stock worth $542,000 after buying an additional 952 shares during the period. Finally, Franklin Resources Inc. raised its stake in Collegium Pharmaceutical by 13.4% during the 3rd quarter. Franklin Resources Inc. now owns 30,625 shares of the specialty pharmaceutical company's stock worth $1,164,000 after buying an additional 3,620 shares during the period.

Collegium Pharmaceutical Stock Down 2.7 %

Shares of NASDAQ COLL traded down $0.75 during trading on Tuesday, hitting $27.03. The stock had a trading volume of 293,366 shares, compared to its average volume of 440,985. Collegium Pharmaceutical, Inc. has a 12 month low of $23.23 and a 12 month high of $42.29. The firm has a fifty day moving average of $28.18 and a two-hundred day moving average of $30.23. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The company has a market capitalization of $868.53 million, a PE ratio of 11.65 and a beta of 0.63.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping analysts' consensus estimates of $1.54 by $0.09. The business had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. As a group, equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

COLL has been the subject of several recent research reports. Piper Sandler decreased their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a report on Tuesday, February 4th. HC Wainwright restated a "buy" rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. StockNews.com lowered shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, April 19th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $46.00 price objective on shares of Collegium Pharmaceutical in a report on Wednesday, April 9th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Collegium Pharmaceutical currently has a consensus rating of "Moderate Buy" and a consensus target price of $43.60.

Insider Buying and Selling

In related news, CFO Colleen Tupper sold 10,445 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $30.01, for a total value of $313,454.45. Following the sale, the chief financial officer now owns 165,246 shares of the company's stock, valued at approximately $4,959,032.46. The trade was a 5.95 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total value of $1,123,200.00. Following the transaction, the executive vice president now directly owns 154,204 shares of the company's stock, valued at approximately $4,330,048.32. This trade represents a 20.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 81,693 shares of company stock valued at $2,334,994. 2.51% of the stock is owned by insiders.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.